Bimzelx (bimekizumab-bkzx) is a dual humanized interleukin 17A and F antagonist biologic therapy administered by subcutaneous injection. It is indicated for the treatment of adults with moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe hidradenitis suppurativa, active nonradiographic axial spondyloarthritis with objective signs of inflammation, and active ankylosing spondylitis. Bimzelx targets IL-17A and IL-17F, cytokines involved in inflammatory and immune processes, particularly in conditions like psoriasis and hidradenitis suppurativa. By inhibiting both IL-17A and IL-17F, Bimzelx suppresses the release of proinflammatory cytokines and chemokines. For psoriasis and hidradenitis suppurativa, the package insert specifically mentions the following adverse reactions: upper respiratory tract infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, Herpes simplex infections, acne, folliculitis, other candida infections, and fatigue. For psoriatic arthritis, it mentions upper respiratory tract infections, oral candidiasis, headache, diarrhea, and urinary tract infections. In clinical practice, candidiasis is likely to be one of the most encountered adverse events with Bimzelx in patients treated for psoriasis, psoriatic arthritis, or hidradenitis suppurativa. Other notable adverse reactions include suicidal ideation and behavior, liver biochemical abnormalities, and inflammatory bowel disease. Clinicians should monitor patients closely for these events. As with other biologics, combining Bimzelx with additional immunosuppressive therapies, such as other biologics or live vaccines, is not recommended. Bimzelx can be used as part of a comprehensive treatment plan for dermatologic conditions, often combined with topicals to optimize patient outcomes. Its dual mechanism of action can offer an effective approach to addressing complex inflammatory pathways in psoriasis, psoriatic arthritis, and hidradenitis suppurativa.